Equities research analysts at JPMorgan Chase & Co. initiated coverage on shares of Isis Pharmaceuticals (NASDAQ:ISIS) in a research note issued to investors on Friday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating and a $37.00 price target on the stock. JPMorgan Chase & Co.’s price objective points to a potential upside of 2.58% from the company’s current price. The analysts noted that the move was a valuation call.
Shares of Isis Pharmaceuticals (NASDAQ:ISIS) opened at 36.07 on Friday. Isis Pharmaceuticals has a 52 week low of $7.56 and a 52 week high of $39.83. The stock has a 50-day moving average of $31.17 and a 200-day moving average of $25.41. The company’s market cap is $4.159 billion.
Isis Pharmaceuticals (NASDAQ:ISIS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.12. The company had revenue of $38.10 million for the quarter, compared to the consensus estimate of $26.76 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was down 19.5% on a year-over-year basis.
A number of other firms have also recently commented on ISIS. Analysts at Stifel Nicolaus raised their price target on shares of Isis Pharmaceuticals from $38.00 to $45.00 in a research note to investors on Tuesday, September 24th. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Isis Pharmaceuticals from $27.00 to $32.00 in a research note to investors on Tuesday, September 24th. They now have a “hold” rating on the stock. Finally, analysts at BMO Capital Markets raised their price target on shares of Isis Pharmaceuticals from $31.00 to $43.00 in a research note to investors on Tuesday, September 24th. They now have an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $34.00.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.